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ABSTRACT 
 
 Treatment regimens for drugs approved for use in swine are derived from 
pharmacokinetic (PK) studies completed in healthy pigs. There are few studies examining the 
impact of disease on pharmacokinetics, and these studies have evaluated a limited number of 
drugs in few species. The same pharmacokinetic parameters were not uniformly affected 
between studies, however, a commonality exists that disease impacts pharmacokinetics. The 
pharmacokinetics of ceftiofur hydrochloride has been broadly investigated in clinically 
normal pigs, but information on the pharmacokinetics in Porcine Reproductive and 
Respiratory Syndrome Virus (PRRSV) and Streptococcus suis co-infected pigs has not been 
reported. 
Original research was conducted to provide additional information on how disease 
affects the PK profile of ceftiofur hydrochloride, a commonly used antimicrobial in swine. A 
PRRSV and Streptococcus suis coinfection model was selected due to the common 
occurrence of this coinfection in the field, its significant impacts on production, and lack of 
effective Streptococcus suis control measures. Study results revealed the pharmacokinetic 
profile of ceftiofur was altered by disease. Coinfected pigs demonstrated a decrease in AUC 
and a reduction in CMAX, but showed an increase in Cl/F and a higher Vz/F.  These alterations 
have implications on treatment regimens when using ceftiofur products, as lower plasma 
concentrations and higher clearance rates reduce the likelihood of achieving effective plasma 
levels relative to Streptococcus suis MICs in the presence of PRRS virus.  
There remains a need for continuing research to evaluate the impact of disease on 
pharmacokinetics. Research should focus on evaluating different disease models and 
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antimicrobial classes, as well as identifying the mechanism behind these changes. 
Information gained needs to be included in the drug approval process to ensure the most 
efficacious dosing regimens are labeled for their respective disease indication.
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CHAPTER 1 
 INTRODUCTION 
 
Antimicrobials approved for use in swine have been studied in healthy pigs to 
determine their pharmacokinetic (PK) profile.  There are few studies evaluating the impact of 
disease on pharmacokinetics and the implications on modifying treatment regimens. 
Effectively managing antimicrobial use for disease treatment is an important responsibility 
for swine veterinarians, which involves detailed knowledge of these agents (Karriker, 2012). 
Pharmacokinetic studies in diseased animals better represent the circumstances where most 
drugs are applied in practice and will allow for treatment regimen modifications in light of 
the altered physiologic status of diseased animals.  The pharmacokinetics of ceftiofur 
hydrochloride has been broadly investigated in clinically normal pigs, but information on the 
pharmacokinetics in Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and 
Streptococcus suis co-infected pigs has not been reported. 
 
Thesis Organization 
 This thesis is organized into three chapters. The first chapter introduces the research 
question and its significance. Chapter one also provides a brief overview of ceftiofur 
hydrochloride, including its pharmacokinetics in healthy swine, and the importance of 
PRRSV and Streptococcus suis coinfections in the field.  Chapter one concludes with an 
extensive literature review on previous studies evaluating disease impact on 
pharmacokinetics in swine, and a selective review in other food-producing animals. Chapter 
two details original research evaluating the impact of an experimental PRRSV and 
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Streptococcus suis coinfection on the pharmacokinetics of ceftiofur hydrochloride in nursery-
aged pigs. The content of this chapter has been submitted to the Journal of Animal Science 
for publication consideration. This research was also presented at the 2014 American 
Association of Swine Veterinarians Conference in Dallas, TX. The final chapter, chapter 
three, summarizes the present research results and discusses their relevance to swine 
practitioners and the swine industry. 
 
Ceftiofur Hydrochloride 
Ceftiofur hydrochloride (Excenel RTU Sterile Suspension, Zoetis, Kalamazoo, MI) is 
a broad spectrum, third generation cephalosporin. Excenel is FDA approved for use in 
treatment/control of swine bacterial respiratory disease associated with Actinobacillus 
pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis and Streptococcus suis. 
The labeled dosage regimen of Excenel for use in swine is 3-5 mg/kg body weight (BW) 
administered intramuscularly (IM) and repeated at 24 hour intervals for a total of three 
consecutive days. 
Ceftiofur’s primary mechanism of action is to interfere with bacterial cell wall 
synthesis.  Ceftiofur binds irreversibly to bacterial penicillin-binding proteins, inactivating 
them and preventing cross-bridge formation. Cross-bridge prevention weakens the 
peptidoglycan layer of bacteria, effectively killing actively growing bacteria (Papich, 2009).  
There are different mechanisms bacteria utilize to gain resistance to ceftiofur products.  
Bacteria can produce cephalosporinases which cleave the beta lactam ring, alter the 
permeability of their cell wall to prevent penetration of ceftiofur products, or alter their 
penicillin binding proteins so they are no longer susceptible to ceftiofur (Papich, 2009). 
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Ceftiofur effectiveness is predicted based upon the time serum concentrations remain 
above the MIC (minimum inhibitory concentration) of the target bacteria during the dosing 
interval.  Dosing regimens are formulated considering this pharmacokinetic principle. For 
optimal antimicrobial response, serum ceftiofur concentrations should cover the MIC for 
50% of the dosing interval when treating gram positive bacteria, and 100% of the dosing 
interval for gram negative bacteria (Papich, 2009).   
Ceftiofur is rapidly and almost completely transformed in the plasma to 
desfuroylceftiofur, the microbiologically active metabolite, and furoic acid (Papich, 2009). 
Desfuroylceftiofur is further metabolized to disulfides and binds to macromolecules in 
plasma and tissues (Beconi-Barker et. al., 1996). Desfuroylceftiofur is minimally 
metabolized by the liver and primarily undergoes renal elimination. It is also a relatively 
polar molecule with low lipid solubility and poor cellular membrane penetration (Papich, 
2009). The high protein binding of desfuroylceftiofur limits diffusion from the plasma to 
tissues, restricts plasma clearance, and prolongs half-life (Papich, 2009). 
Ceftiofur is considered an important antibiotic to human medicine and the Food and 
Drug Administration (FDA) finds it critical to preserve ceftiofur’s effectiveness.  The FDA 
has prohibited certain extralabel drug uses (ELDU) of ceftiofur products out of concern 
ELDU in food producing animals may contribute to cephalosporin-resistant strains of 
bacteria. Under current regulations, ceftiofur products can be used to treat or control an 
extralabel disease indication, but must be used in the species for which it’s approved and 
according to the labeled dosage regimen (dose, route, frequency, and duration of 
administration) (Federal Register, 2012). 
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Efficacy of ceftiofur is primarily predicted by the amount of time plasma 
concentrations exceed the MIC (minimum inhibitory concentration) for the target bacteria as 
opposed to the magnitude of the concentration above MIC. The time plasma ceftiofur 
concentrations remain above MIC during the dosing interval is the main criteria used in 
developing treatment regimens (Riviere, 2009).  Alterations in the PK profile of ceftiofur 
products which affect the duration above MIC would negatively impact treatment outcomes. 
The primary factor affecting duration above MIC is half-life, but this is also affected by the 
initial maximum serum concentration.  A reduction in half-life would require more frequent 
dose administration to maintain sufficient time above MIC. Half-life is physiologically 
dependent on the volume of distribution and the plasma clearance (Riviere, 2009). An 
increase in volume of distribution generally lengthens the half-life as less of the drug is 
exposed to elimination per unit of time. An increase in plasma clearance shortens the half-life 
as more of the plasma is being cleared of the drug per unit time. Alterations in plasma 
clearance and volume of distribution which reduce half-life would also effect the time above 
MIC and clinical efficacy of treatment regimens. 
  
Porcine Reproductive and Respiratory Syndrome and Streptococcus suis Coinfections 
Porcine Reproductive and Respiratory Syndrome Virus is an economically important 
disease which causes reproductive impairment in breeding animals and respiratory disease in 
pigs of all ages (AASV, 2009).  Infection with PRRSV increases susceptibility to bacterial 
infections in nursery and grow-finish pigs (Halbur, 2000). Coinfection with PRRSV and 
Streptococcus suis occurs commonly in the field and can be difficult to control with 
medication and vaccination regimens (Halbur, 2000). Streptococcus suis is a common swine 
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pathogen typically seen in recently weaned and nursing pigs. It causes systemic disease 
characterized by septicemia, meningitis, polyarthritis, polyserositis, and bronchopneumonia 
(AASV, 2009). Controlling primary pathogens which interact with Streptococcus suis is 
important in reducing its incidence and improving response to treatment (AASV, 2009). The 
common occurrence of PRRSV and Streptococcus suis coinfections, their significant impacts 
on production, and the lack of highly effective measures to control Streptococcus suis 
illustrate the need to evaluate their effects on the pharmacokinetics of antimicrobials used in 
swine. 
 
Pharmacokinetics of Ceftiofur Hydrochloride in Healthy Swine 
Ceftiofur hydrochloride has been evaluated in healthy animals to determine its 
pharmacokinetic behavior in a limited number of studies. Ceftiofur hydrochloride is 
metabolized similar to ceftiofur sodium (Naxcel, Zoetis, Kalamazoo, MI), a previously 
approved antimicrobial in swine, allowing Naxcel to serve as the basis for approval and dose 
determination of Excenel in swine.  A study by Brown and colleagues (1999) evaluated the 
plasma pharmacokinetics of ceftiofur hydrochloride in pigs after a single IM injection. In this 
study twenty-six healthy, crossbred Yorkshire pigs were utilized. Twelve pigs received a 
3mg/kg BW dose of ceftiofur hydrochloride and fourteen pigs received a 5 mg/kg BW dose.  
Blood samples were collected serially for up to 96 hours post injection to characterize the 
plasma concentration curve. Plasma samples were analyzed utilizing a validated high 
performance liquid chromatography (HPLC) assay to measure ceftiofur and 
desfuroylceftiofur-related metabolites. In healthy pigs administered the 3 mg/kg dose, the 
CMAX of ceftiofur hydrochloride was 11.8 µg/mL with TMAX ranging from 1-4 hours after 
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injection.  The AUC was 216 ± 28.0 µg*h/mL with a half-life of 16.7 hours.  In pigs 
administered the 5 mg/kg dose, the CMAX was 29.7 µg/mL with TMAX ranging from 0.66 to 2 
hours after injection.  The AUC was 382 ± 89.8 µg*h/mL with a half-life of 15.8 hours.  
Additionally a threshold plasma concentration of 0.2 µg/mL was selected as it exceeded the 
MIC of 0.06 µg/mL for ceftiofur against Pasturella multocida, Actinobacillus 
pleuropneumoniae, and Streptococcus suis (Yancey et al., 1987) providing a conservative 
efficacy estimate. The T > 0.2 was greater than 72 hours at both the 3mg/kg and 5 mg/kg 
doses indicating once daily administration is sufficient to keep plasma concentrations above 
the previously reported MIC for these pathogens (Brown et al., 1999).  
A study by Beconi-Barker and colleagues (1996) evaluated the plasma distribution of 
various ceftiofur hydrochloride doses in swine after IM injection for three consecutive days. 
In this study12 mixed breed swine were utilized and divided evenly into two groups to 
receive 4.41 or 6.76 mg of ceftiofur free acid equivalents (CFAE) per kg BW respectively. 
Blood samples were collected at various time points for up to 24 hours following each dose. 
Plasma samples were analyzed using a validated HPLC assay to look for ceftiofur and related 
metabolites. The cumulative area under the concentration curve (AUC 0-term), maximum 
observed concentration (CMAX) and concentration at slaughter time (Cterm) in plasma were 
calculated for both doses. Animals receiving the 4.41 mg*CFAE/kg BW dose had an average 
AUC 0-term of 793.99 µg*h*mL, CMAX of 26.88 µg/mL, and Cterm of 12.28 µg/mL.  At the 
6.76 mg*CFAE/kg BW dose, animals had an average AUC 0-term of 1043.65 µg*h*mL, CMAX 
of 35.33 µg/mL, and Cterm of 16.67 µg/mL.  Additionally, the highest plasma concentrations 
were achieved at two hours following each treatment. This study concluded ceftiofur 
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distribution after several IM Excenel administrations was similar to that previously reported 
for ceftiofur sodium (Beconi-Barker et al., 1996). 
 
Impact of Disease on Pharmacokinetics in Swine 
There are relatively few studies evaluating the impact of disease on pharmacokinetics 
of antimicrobials for use in swine. Table 1 summarizes these study results, including the 
specific PK alterations seen according to disease model. The effects of PRRSV and 
Streptococcus suis coinfection on pharmacokinetics has not been previously studied, 
however, the pharmacokinetic effects of each of these pathogens has been evaluated 
separately. A study by Tantituvanont and colleagues (2009) evaluated the pharmacokinetics 
of ceftiofur hydrochloride in 4 week old pigs infected with PRRSV.  Pigs were administered 
a 3 mg/kg IM dose of ceftiofur hydrochloride at 7 days post infection with a Thai PRRSV 
isolate. Plasma ceftiofur concentrations were measured using HPLC and pharmacokinetic 
parameters were analyzed using a non-compartmental model. Pharmacokinetic analysis 
revealed significant differences (P <0.01) in PK parameters between control and PRRSV 
infected pigs.  Infected pigs had a 116% increase in Vz/F (volume of distribution per fraction 
of dose absorbed) and a 234% increase in Cl/F (plasma clearance per fraction of dose 
absorbed) compared to non-infected pigs. Additionally, the CMAX and AUC for infected pigs 
decreased by 54% and 70% when compared to non-infected pigs, and the half-life was 
reduced from 21.0 hours to 16.0 hours on average in infected pigs. The conclusions from this 
study suggested pharmacokinetic parameters of ceftiofur hydrochloride were altered as a 
consequence of PRRSV infection. The authors proposed decreased plasma protein binding 
resulted in increased plasma clearance, increased volume of distribution, and shortened half-
8 
 
life, although changes in total protein or protein binding were not measured. They stated 
reduced protein binding would lead to increased fractions of free desfuroylceftiofur (DFC). 
Free DFC is more readily exposed to renal elimination resulting in increased ceftiofur 
clearance and decreased half-life.  A greater portion of free ceftiofur is available for tissue 
deposition leading to an increased volume of distribution. The authors further suggested 
alterations in dosage regimens may be warranted to achieve maximum efficacy of ceftiofur 
hydrochloride treatment against secondary bacterial pathogens in PRRSV infected pigs 
(Tantituvanont et al., 2009). 
The impact of PRRSV infection on pharmacokinetics was again evaluated in a study 
by Godoy and colleagues (2010). The pharmacokinetics of amoxicillin administered ad 
libitum in medicated feed was evaluated in healthy and respiratory diseased pigs. Diseased 
pigs had a naturally occurring respiratory infection with PRRSV in addition to secondary 
bacterial agents isolated from lung tissue at the study’s conclusion. Isolated bacterial agents 
included Pasturella multocida, Bordetella bronchiseptica, and Streptococcus suis.  Diseased 
pigs received amoxicillin in medicated feed at a mean dose of 9 mg/kg/day for five 
consecutive days. Plasma concentrations of amoxicillin were determined using HPLC and 
pharmacokinetic analysis utilized a non-compartmental approach. Diseased animals 
compared to healthy animals had larger values at steady state of AUC, CMAX, and CMIN, as 
well as longer absorptive periods (4-6 hours versus 2 hours). The authors attributed these 
differences to the significantly greater bioavailability (14.1% to 44.7%) in diseased pigs 
which may occur from reduced intestinal transit rate increasing the extent of drug absorption. 
Intestinal transit rate was not directly measured  in this study. The results of this research 
suggest the pharmacokinetic behavior of amoxicillin after oral administration is modified in 
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the disease state and influenced by animal feeding behavior.  Dosage regimens, when using 
medicated feed, should consider these alterations in PK parameters and the potential effects 
on gastrointestinal transit time to optimize treatment efficacy (Godoy et al., 2010). 
The effects of Streptococcus suis infection on the pharmacokinetics of potassium 
penicillin G was investigated by Zeng and Fung (1990) in three month old healthy (n=8) and 
Streptococcus suis infected (n=6) pigs after IM injection at a dose of 15,000 iu/kg.  
Streptococcus suis inoculation was completed using 108 to 109 colony forming units of three 
Streptococcus suis strains (C74-41, C74-42, and C74-43) isolated from infected pigs in 
Guangdong, China. Penicillin was administered in challenged pigs after the rectal 
temperature of each pig had increased by 1.5 °C. Serum concentrations of penicillin G were 
analyzed microbiologically using a modified agar-well diffusion technique. Pharmacokinetic 
analysis was completed using a one-compartment open model with the assumption 
bioavailability (F) was normal and approximately 100%. This represents a limitation in this 
study, as previous research suggests bioavailability is altered as a consequence of infection. 
Additionally, the bioavailability for non-IV routes of administration is typically lower than 
100%. Pharmacokinetic analysis revealed differences in the PK parameters between healthy 
and Streptococcus suis infected pigs. Infected pigs experienced reduced maximum serum 
concentrations (CMAX) and area under the serum concentration-time curve (AUC), but 
experienced increased volume of distribution (Vd) and body clearance (ClB). The authors 
concluded increased ClB may be explained by increased renal blood flow as a consequence of 
fever. The increased Vd may have resulted from decreased protein binding in addition to 
fever and inflammation increasing the ability of penicillin G to penetrate cellular membranes. 
The alterations in ClB and Vd subsequently led to alterations in the serum concentrations of 
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Penicillin G in Streptococcus suis infected pigs. The study concluded fever and inflammation 
induced by Streptococcus suis infection may enhance the ability of Penicillin G to penetrate 
cellular membranes (Zeng and Fung, 1990). 
The pharmacokinetics of both ampicillin and sulfadimidine in healthy and 
Streptococcus suum challenged pigs were studied by Yuan and colleagues (1997). Twenty 
three pigs, 60-70 days of age, were randomly assigned into three groups to evaluate 
ampicillin administered at 10 mg/kg IV, 10 mg/kg IM, and sulfadimidine at 50 mg/kg IV. An 
initial PK assessment was completed in these three groups as healthy pigs. Following a ten 
day washout period animals were inoculated with 1.25 x 109 Streptococcus suum organisms 
subcutaneously and a second PK assessment conducted five days post infection. Ampicillin 
concentrations in serum where determined using microbiological methods and sulfadimidine 
serum concentrations were detected using HPLC. A non-linear least squares method was 
used to calculate PK parameters. Between infected and non-infected animals, ampicillin PK 
parameters were statistically different when administered IV, but no difference was seen after 
IM administration. Infected pigs after IV administration experienced increased volume at 
steady-state (Vss), body clearance (ClB), and central elimination rate constant (k10).  These 
alterations lead to a decreased area under the curve (AUC). Following IV administration of 
sulfadimidine, the ClB was decreased, half-life (t 1/2) prolonged, and AUC increased. The 
conclusions of this study suggested the increased volume of distribution of ampicillin may be 
attributed to decreased protein binding in addition to vascular wall damage occurring during 
infection. In regards to sulfadimidine, the study concluded decreased clearance in infected 
pigs could result from dysfunction of glomerular filtration. Decreased clearance leads to a 
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prolonged half-life.  The results of this study suggest the pharmacokinetics of ampicillin and 
sulfadimidine were affected differently by the same disease process (Yuan et al., 1997). 
Actinobacillus pleuropneumoniae (APP), a highly contagious cause of 
pleuropneumoniae in swine, has been evaluated to determine its effects on pharmacokinetics 
in several studies.  Liu et al. (2003) studied the pharmacokinetics of florfenicol after IV, IM, 
and oral administration (20 mg/kg dose) in APP infected pigs. Eighteen crossbred pigs, 
approximately seven weeks of age, were evenly divided to receive IV, IM, or oral florfenicol.  
An initial PK assessment was conducted in all three groups prior to disease inoculation, 
which was followed by a two-week washout period. Animals were subsequently inoculated 
via tracheal injection with 3.5 × 107 to 4 × 107 CFU of APP Serotype 1 and the second PK 
assessment initiated 3.5 hours after inoculation.  Disease challenge was confirmed through 
clinical signs and x-rays prior to the second PK assessment, and through histologic 
examination and organism isolation at conclusion of the study. Concentrations of Florfenicol 
were evaluated utilizing HPLC and pharmacokinetic analysis utilized a one-compartment 
model for IM administration and two-compartment model for IV and oral routes. Results of 
pharmacokinetic analysis showed no statistically significant differences between the PK 
profile of florfenicol in healthy and diseased pigs following IM, IV, or PO administration. 
The authors hypothesized the lack of difference between healthy and diseased pigs may be 
attributed to APP causing extensive respiratory lesions as opposed to affecting the liver and 
kidneys. Disease processes which affect these organs would be more likely to affect the 
distribution of florfenicol (Liu et al., 2003). 
The impact of APP infection and dexamethasone on pharmacokinetics was evaluated 
in a study by Post et al. (2002), in pigs after IV administration of enrofloxacin at 5 mg/kg 
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BW. Twenty-four barrows were used in a 2 x 2 factorial design of treatment groups. APP 
inoculation was performed by endobronchial infusion of serotype 1 strain L91-2 
administered 24 hours prior to enrofloxacin administration. Dexamethasone administration 
was performed IV at 0.5 mg/kg BW dose at 36, 24, and 12 hours prior to enrofloxacin 
administration. Plasma samples were analyzed for enrofloxacin and its metabolite 
ciprofloxacin using HPLC and pharmacokinetic parameters analyzed using a non-
compartmental model. APP infected pigs administered dexamethasone in addition to 
enrofloxacin experienced reduced AUC and half-life, but increased plasma clearance, volume 
of distribution, and elimination rate constant.  Healthy pigs administered Dexamethasone in 
combination with enrofloxacin experienced the same PK alterations as APP-infected animals 
co-administered dexamethasone with the exception of volume of distribution which was not 
statistically different.  APP infected pigs administered enrofloxacin alone experienced no 
difference in AUC or clearance, but exhibited decreased volume of distribution and half-life, 
and an increased elimination rate constant. This study concluded that dexamethasone results 
in a generalized effect on the PK profile of enrofloxacin while APP infection has a more 
selective impact on PK parameters. APP infection reduced the volume of distribution, 
subsequently reducing half-life, but did not appear to affect enrofloxacin metabolism. 
Dexamethasone treated pigs experienced increased clearance which may be due to increased 
glomerular filtration from glucocorticoid administration. The authors concluded that the 
minor changes seen in the PK profile of enrofloxacin in APP infected pigs were unlikely to 
affect antimicrobial efficacy (Post et al., 2002). 
APP infection was further evaluated by Agerso and colleagues (1998) to determine 
the impact on amoxicillin pharmacokinetics when administered IV at a dose of 8.6 mg/kg 
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BW. A total of eighteen male pigs were inoculated by use of an aerosol infection model with 
serotype 2, strain 4226 of APP. Twenty hours after infection amoxicillin was administered. 
Plasma concentrations of amoxicillin were evaluated using HPLC and pharmacokinetic 
analysis conducted using a three-compartment open model.  This study utilized previously 
reported PK parameter values for amoxicillin in healthy pigs to establish normal values for 
comparison. The results of this study found no significant difference in PK parameters of 
amoxicillin compared to those previously reported in healthy pigs (Agerso and Friis 1997). 
Infected pigs did have an increased steady state volume of distribution, but this effect was not 
statistically different. The authors concluded it was unclear whether these observed 
differences warrant evaluations of treatment strategies given the lack of statistical 
significance. Study results were not compared with previous research. The authors stated it is 
difficult to compare alterations in PK parameters between studies in other experimentally 
infected animals due to the multitude of factors involved (Agerso et al., 1998).  
The impact of APP on pharmacokinetics was again investigated after IV 
administration of sulfonamide/trimethoprim combinations to clinically healthy pigs and the 
same pigs three hours following endobronchial challenge (Mengelers et al., 1995). Pigs were 
administered sulfadimethoxine (SDM) or Sulfamethoxazole (SMX) at 25 mg/kg BW dose in 
combination with trimethoprim (TMP) at 5 mg/kg BW. The plasma concentrations of these 
drug combinations were determined by HPLC and pharmacokinetic analysis performed using 
a one-compartment open model. The pharmacokinetic profiles of the sulfonamides were not 
significantly different between healthy and APP infected pigs. The PK profile of 
trimethoprim was altered as a consequence of disease, with APP infected pigs experiencing a 
reduced AUC, increased volume of distribution, and increased clearance. The study 
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concluded minor differences were present in the PK profile of TMP in APP infected pigs. 
Additionally, study results showed the half-lives of SMX and TMP were of similar duration 
making this antimicrobial combination preferred over SDM and TMP co-administration 
(Mengelers et al., 1995).  
Pijpers et al. (1990) evaluated the pharmacokinetics of oxytetracycline (OTC) 
following IV administration in healthy and APP challenged pigs.  Two groups of seven pigs 
were administered IV oxytetracycline at 10 and 50 mg/kg respectively. OTC was 
administered in clinically healthy pigs and again seven days later at three hours post 
endobronchial challenge with APP toxins. All plasma samples were analyzed for OTC using 
bioassay and plasma samples collected at 9, 16, and 24 hours after drug administration were 
additionally analyzed by HPLC. The pharmacokinetic analysis was completed using a two-
compartment model.  Pneumonic pigs experienced a decreased distribution-rate constant, 
increased elimination rate constant, and decreased volume of distribution (P < 0.05). The 
half-life was approximately 6 hours in healthy animals and 5 hours in diseased pigs. There 
were no statistically significant differences in the pharmacokinetic profile of pigs 
administered the 10 mg/dose of OTC compared to those administered 50 mg/kg. The study 
concluded pharmacokinetic differences existed between healthy and pneumonic pigs 
following IV administration of OTC and further experiments examining more practical 
routes of administration were needed to evaluate the need for treatment regimen 
modifications (Pijpers et al., 1990). 
A follow-up by Pijpers et al. (1991) examined the differences in pharmacokinetic 
parameters of orally administered oxytetracycline at 50 mg/kg BW dose in clinically healthy 
pigs and in the same pigs following a challenge with APP toxins. Plasma OTC concentration 
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and pharmacokinetic analysis were completed as described in the previous study.  After 
challenge, pigs showed variation in oxytetracycline plasma concentrations and significant 
differences in pharmacokinetic parameters (P < 0.05). Challenged pigs had a reduced CMAX 
and body clearance, but an increased area under the curve (AUC ) and volume of 
distribution. The mean maximum plasma concentration was also achieved significantly later 
at 7.0 hours in pneumonic pigs compared to 1.74 hours prior to disease challenge.  The 
authors concluded only healthy pigs should be administered drugs via feed or water due to 
the appetite suppression and reduced water consumption observed in pneumonic pigs during 
this study. They also concluded withdrawal times should be prolonged when treating sick 
pigs to compensate for an extended half-life (Pijpers et al., 1991). 
The effect of salmonellosis in swine on the pharmacokinetics of antimicrobials has 
been evaluated in two different studies.  Salmonella infections can be asymptomatic or cause 
disease manifested as septicemia or enterocolitis (AASV, 2009). The impact of Salmonella 
typhimurium infection on the pharmacokinetics of danofloxacin, a fluoroquinolone, 
administered IV at a dose of 2.4 mg/kg BW was evaluated in a study by Lindecrona and 
colleagues (2000). A total of 24 male pigs were utilized for the study which were evenly 
divided into a control and disease group. Inoculation of the disease group was performed 
intragastrically via a stomach tube with 5.5 × 1010CFU of Salmonella typhimurium. Twenty-
four hours post inoculation the PK assessment occurred in both inoculated and control 
animals. Danofloxacin concentrations in plasma were determined using HPLC and a non-
compartmental model was utilized for pharmacokinetic analysis. In Salmonella infected pigs, 
the mean elimination half-life was increased from 6.7 to 9.4 hours resulting from decreased 
body clearance in infected pigs. Diseased animals also had a significant reduction in the 
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volume of the peripheral compartment. These changes in PK parameters lead to an increase 
in the area under the curve. The authors concluded prolonged half-life and reduced body 
clearance may be attributed to a reduced metabolic capacity occurring during infection 
(Lindecrona et al., 2000). 
The pharmacokinetic impact of Salmonella typhimurium was again investigated, but 
in pigs administered amoxicillin IM at 15 mg/kg BW dose (Agerso et. al., 2000).  In this 
study 24 healthy gilts were utilized and divided evenly into a control and challenge group. 
Salmonella inoculation was performed intragastrically by use of a stomach tube with 6 x 
1010CFU of Salmonella strain NVL810. Amoxicillin was administered 24 hours after 
inoculation and blood samples collected in both diseased and healthy pigs.  Plasma 
amoxicillin concentrations were determined by HPLC and pharmacokinetic analysis 
conducted using a one-compartment model with first order absorption.  Salmonella-
inoculated pigs experienced changes in the plasma concentration-time profile. Diseased 
animals had an increase in the absorption rate constant, a prolonged elimination half-life, and 
an increased volume of distribution. The authors attributed the increased absorption rate 
constant in infected pigs to increased body temperature and accompanying muscle shivering 
which would lead to increased blood flow at the site of drug injection. The prolonged half-
life in inoculated animals was explained by the increased volume of distribution which may 
result from alteration in blood flow as a consequence of infection. This study showed 
Salmonella typhimurium inoculation altered the pharmacokinetics of amoxicillin. The authors 
concluded inflammation alone may not be responsible for changes in the kinetics of a drug, 
but alterations in blood flow may play an important role (Agerso et. al., 2000). 
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Another enteric pathogen of swine, Escherichia coli, has been evaluated to determine 
its effects on drug pharmacokinetics. A study by Jensen et. al. (2006), evaluated the 
pharmacokinetics of amoxicillin administered orally in the water at a mean dose of 26-32 
mg/kg BW in pigs with experimentally induced E. coli diarrhea.  A total of 24 recently 
weaned, crossbred pigs were utilized with 10 pigs undergoing inoculation and 14 serving as 
control animals. Pigs were inoculated via gastric tube with a daily dose of 109 CFUs of E. 
coli O149:F4 until diarrhea developed or for a maximum of three days. Amoxicillin 
administration occurred through the water for a duration of four hours for two consecutive 
days. Plasma amoxicillin concentrations were evaluated using HPLC and pharmacokinetic 
analysis was fitted to an open one-compartment model.  Pigs with E. coli induced diarrhea 
experienced a reduced AUC and CMAX compared to healthy pigs on Day 1 of water 
medication, but no differences were appreciated on Day 2 of administration.  Diseased 
animals also had a delayed TMAX and a prolonged half-life on Day 1 compared to healthy 
animals. The authors hypothesized the reduced CMAX and AUC occurring in disease pigs may 
result from a reduction in intestinal absorption. Diseased animals had a reduction in the time 
plasma concentrations remained above the MIC, 0.025 µg/mL, thus reducing the therapeutic 
efficacy of amoxicillin in diarrheic pigs. The authors suggested using a higher initial dose of 
amoxicillin when water medicating for treatment of E. coli diarrhea in recently weaned pigs 
(Jensen et al., 2006). 
The effect of E. coli was further evaluated in combination with dexamethasone to 
determine its impact on Enrofloxacin in pigs after IV administration at 5 mg/kg BW (Post et 
al., 2003). Twenty-four barrows were used in a 2 x 2 factorial design of treatment groups 
with the main effects being LPS inoculation and dexamethasone administration. E. coli 
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055:B5 LPS inoculation was performed IV 24 hours prior to enrofloxacin administration.  
Dexamethasone administration was performed IV at 0.5 mg/kg BW dose at 42, 24, and 12 
hours prior to enrofloxacin administration. Plasma samples were analyzed for enrofloxacin 
and its metabolite ciprofloxacin using HPLC and pharmacokinetic parameters were analyzed 
using a non-compartmental model. Pigs administered dexamethasone in addition to 
enrofloxacin and E. coli infected animals co-administered dexamethasone both experienced 
an increased volume of distribution. E. coli LPS infected pigs experienced an increased AUC 
and elimination half-life, but decreased plasma clearance and elimination rate constant. This 
study concluded dexamethasone administration in LPS infected animals returned the AUC, 
clearance, and half-life values for enrofloxacin to values consistent with control animals. The 
authors contributed this finding to dexamethasone administration inhibiting the production of 
inflammatory mediators. This supports the notion that alterations in PK parameters result 
from LPS induced inflammation (Post et al., 2003). 
 
Impact of Disease on Pharmacokinetics in Other Food-Producing Animals 
Additional studies examining the pharmacokinetics in diseased animals have been 
completed in other species.  The results and conclusions from these studies may not be 
directly applicable to swine, given the biological variation between species, but these studies 
further support alterations in the pharmacokinetics of antimicrobials as a consequence of 
disease.  There are a limited number of trials conducted in other species which evaluate 
ceftiofur products specifically. One study by Amer et al. (1998), examined the effects of 
aflatoxicosis on the kinetic behavior of ceftiofur sodium in chickens.  Chickens were divided 
evenly into a control and aflatoxin treated group which received 0.75 ppm of aflatoxin B1 
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orally in the feed for 30 days. An initial PK assessment was performed in both groups with 
ceftiofur sodium administered at a 10 mg/kg BW dose IV. Following a two-week drug 
washout period, the control and challenge groups were divided evenly into two subgroups to 
receive ceftiofur sodium orally or IM both at a 10 mg/kg BW dose. Ceftiofur serum 
concentrations were analyzed microbiologically.  Pharmacokinetic analysis revealed animals 
exposed to aflatoxin experienced significantly lower serum ceftiofur concentrations 
following IV and oral administration.  Following IV administration in aflatoxin treated 
chickens, a shortened elimination half-life, increased volume of distribution, and increased 
body clearance were appreciated.  Following oral administration in aflatoxin treated chickens 
a longer half-life and time to maximum serum concentration (TMAX) occurred. The authors 
concluded the changes in the PK profile of ceftiofur sodium in aflatoxin treated animals 
likely resulted from inflammation in different organs affecting the absorption, distribution, 
metabolism, and excretion of ceftiofur. The reduced serum concentrations in infected 
chickens following IV administration was supported by a higher elimination rate and higher 
clearance rate. The authors concluded low serum concentrations may be attributed to 
enhanced ability of the drug to penetrate diseased tissues. Oral administration in infected 
turkeys resulted in a prolonged half-life which the authors hypothesized was the result of 
reduced ceftiofur absorption from the intestine as a consequence of aflatoxin induced 
gastroenteritis. Additionally, hypoproteinaemia resulting from aflatoxicosis may allow for 
additional unbound drug to be presented for renal elimination. The results of this study 
suggested adjustments to treatment regimens may be warranted in the presence of 
aflatoxicosis to ensure effective concentrations of ceftiofur are present at the site of infection 
for sufficient duration (Amer et al., 1998). 
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Several studies have been conducted evaluating the impacts of disease on non-
ceftiofur antimicrobials in a range of species. A study by Anika and colleagues (1986) 
evaluated the pharmacokinetics of antimicrobial agents in healthy dwarf goats and those 
infected with Ehrlichia phagocytophila (tick-born fever).  Infected goats had prolonged 
elimination half-life values for sulphadimidine and oxytetracyline (Anika et al., 1986). A 
study by Groothuis et al. (1980), examined the effect of E. coli endotoxin induced fever on 
the pharmacokinetics of ampicillin, trimethoprim, and chloramphenicol after intravascular, 
intramuscular, and oral administration in calves. During the febrile period, serum levels of 
chloramphenicol, ampicillin, and amoxicillin were lower after IM and oral administration. 
Additionally the half-life of trimethoprim after IV injection was longer and the volume of 
distribution greater (Groothuis et al., 1980).  Ranjan and colleagues (2011) examined the 
effect of fever induced with E. coli endotoxin on the pharmacokinetic profile of ceftriaxone 
administered at 50mg/kg IV in sheep.  In febrile animals, CMAX was 16.33% lower and half-
life was also prolonged. The volume of distribution was higher in febrile sheep while AUC 
and plasma clearance remained unchanged. The authors of this study suggested increased 
capillary permeability caused by chemical mediators released during fever led to greater 
antimicrobial distribution (Ranjan et al., 2011). The above studies, while in different species 
and examining different classes of antimicrobials, show an effect of disease on 
pharmacokinetics, particularly in the febrile state.  
 
Summary  
The few studies examining the impact of disease on pharmacokinetics evaluated a 
limited number of drugs in few species. The same pharmacokinetic parameters were not 
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uniformly affected between studies, however, a commonality exists that disease impacts 
pharmacokinetics.  It is challenging to draw conclusions across different studies about 
specific changes in PK parameters resulting from experimental infection, as there are many 
factors involved including: the disease model, inoculum concentration, antimicrobial class 
evaluated, species, and the animal’s response to infection (Agerso et. al., 1998).  This is 
illustrated when evaluating studies conducted on APP infection and its impact on 
pharmacokinetics.  Studies utilized different routes of infection and incubation periods, 
which likely contributed to the variation in study results. Additionally, the different PK 
parameters affected between studies and ranges in magnitude of effect, indicate this 
relationship is likely disease and antimicrobial dependent.  This supports the need for 
additional pharmacokinetic studies examining multiple antimicrobial classes and disease 
challenge models. The effects on pharmacokinetics as a consequence of disease also illustrate 
the need for PK studies completed in both diseased and healthy animals to be included in the 
drug approval process. 
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CHAPTER 2 
IMPACT OF AN EXPERIMENTAL PRRSV AND STREPTOCOCCUS SUIS CO-
INFECTION ON THE PHARMACOKINETICS OF CEFTIOFUR HYDROCHLORIDE 
AFTER INTRAMUSCULAR INJECTION IN PIGS 
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Abstract 
The objective of this study was to determine the impact of an experimental Porcine 
Reproductive and Respiratory Syndrome Virus (PRRSV) and Streptococcus suis coinfection 
on the pharmacokinetic (PK) profile of ceftiofur hydrochloride in pigs after intramuscular 
(IM) injection. Eighteen clinically normal crossbred gilts, 7 wk of age, were sourced from a 
PRRSV negative herd with no clinical signs of Streptococcus suis infection. Animals were 
ranked and randomly assigned by weight into a challenge group (ten pigs) and control group 
(eight pigs) which were housed separately. The first PK assessment occurred in both groups 
before disease challenge. Pigs received a single IM injection of ceftiofur hydrochloride 
(Excenel RTU Sterile Suspension, Zoetis, Kalamazoo, MI) at a 5 mg/kg BW dose. Blood 
samples were collected from both groups at 0, 10, 20, 40, 60 min and at 2, 4, 8, 16, 24, 36, 
and 48 h post injection to characterize the plasma concentration curve. After a 10 day drug 
washout period, the challenge group was inoculated with 2 mL of PRRSV isolate VR-2385 
(105.75 50% tissue culture infective doses per mL) intranasally (IN). Eight days after PRRSV 
inoculation, the same pigs were inoculated with 2 mL of Streptococcus suis serotype 2 (1.23 
x 109 cfu/mL) IN. When clinical disease was evident in greater than 50% of the pigs in the 
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challenge group, the second PK assessment began in both challenge and control groups using 
the same collection schedules. Ceftiofur and related metabolites were measured using a 
liquid chromatography-mass spectrometry technique. Plasma concentration-time curves were 
analyzed using a non-compartmental model. A mixed model ANOVA was used to compare 
PK parameters. Coinfected pigs demonstrated lower values of area under the curve (AUC) 
(P=0.0050) and maximum serum concentration (CMAX) (P=0.0069), but higher values of 
plasma clearance per fraction of dose absorbed (Cl/F) (P=0.0019) and volume of distribution 
per fraction of dose absorbed (Vz/F) (P=0.0054) indicating drug kinetics were altered by 
infection. Comparisons completed on the same animals reduced biological variation and 
increased statistical power as indicated by CMAX  which was not statistically significant when 
comparing across control and challenge groups at the second PK (P=0.4682) assessment, yet 
was significant when comparing the same pigs before and after challenge (P=0.0069). The 
data from this study has implications on ceftiofur treatment regimens in diseased pigs. 
 
Introduction 
Treatment regimens for drugs approved for use in swine are derived from 
pharmacokinetic (PK) studies completed in healthy pigs. There are few studies evaluating 
how disease impacts drug pharmacokinetics and the implications for modifying treatment 
regimens. One study which has been completed demonstrated mean maximum plasma 
tetracycline concentration (CMAX) was lower and achieved significantly later post 
administration in pneumonic pigs relative to healthy pigs (Pijpers et al., 1991). In a second 
study, pigs infected with porcine reproductive and respiratory syndrome virus (PRRSV) had 
decreased plasma ceftiofur concentrations relative to healthy pigs (Tantituvanont et al., 
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2009). Pharmacokinetic studies in diseased animals better represent the circumstances where 
most drugs are applied in practice, and will allow for modification of treatment regimens and 
drug withdrawal times in light of the altered physiologic status of diseased animals.  
Streptococcus suis is a bacterium which typically infects younger pigs and commonly 
leads to a septicemia, meningitis, arthritis, endocarditis, and pneumonia (Gottschalk, 2012). 
Infection with PRRSV causes respiratory disease and reproductive failure, which is estimated 
to cost the united states swine industry $664 million annually (Holtkamp et al., 2013). 
Susceptibility of pigs to bacterial infection is increased during PRRSV viremia (Halbur et al., 
2000). Ceftiofur hydrochloride is a bactericidal third generation cephalosporin which inhibits 
bacterial cell wall synthesis. Ceftiofur is effective against gram positive and negative 
bacteria, and approved by the FDA for use in swine.  
The objective of this study was to determine the impact of experimental PRRSV and 
Streptococcus suis co-infection on the pharmacokinetics of ceftiofur hydrochloride after 
intramuscular (IM) injection at 5 mg/kg BW. We tested the null hypothesis that the PK 
profile of ceftiofur would not differ between healthy and PRRSV Streptococcus suis 
coinfected pigs. 
 
Materials and Methods 
Prior to initiation of this experiment, all study procedures described were reviewed 
and approved by the University’s Institutional Animal Care and Use Committee (IACUC 
protocol # 5 - 12 -7380 - S). 
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Drugs 
Ceftiofur hydrochloride (Excenel RTU Sterile Suspension, Zoetis, Kalamazoo, MI) 
was the antimicrobial evaluated. Ceftiofur hydrochloride is indicated for treatment and 
control of swine bacterial respiratory disease associated with Actinobacillus 
pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis and Streptococcus suis. 
Ceftiofur hydrochloride is labeled at a dosage of 3-5 mg/kg BW given IM every 24 h for 
three consecutive days. Each milliliter of ready-to-use sterile suspension contains ceftiofur 
hydrochloride equivalent to 50 mg ceftiofur, 0.50 mg phospholipon, 1.5 mg sorbitan 
monooleate, 2.25 mg sterile water for injection, and cottonseed oil. All Excenel used in this 
study was from the same lot number and stored according to manufacturer recommendations. 
 
Study Animals  
All live animal study procedures were conducted at the Iowa State University 
Livestock Infectious Disease Isolation Facility. Eighteen clinically healthy crossbred gilts, 
seven wk of age, were sourced from a PRRSV negative herd. Pigs tested PRRSV PCR and 
ELISA negative on serum and Porcine Circovirus Type 2 (PCV2) negative on oral fluids 
PCR. All animals were free of clinical signs consistent with Streptococcus suis infection 
including central nervous system (CNS) signs, ataxia, or fever. No evidence of Streptococcus 
suis was observed at the source farm. Pigs and their dams had no history of vaccination 
against or exposure to PRRSV or Streptococcus suis. Pigs were ranked and randomly 
assigned by weight into a challenge group (ten pigs) and a control group (eight pigs), which 
were housed separately to prevent disease transmission between groups. Within their 
respective groups, pigs were group housed in a single pen measuring 3.66 m in length x 3.05 
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m in width x 1.22 m in height with a solid concrete floor. Pigs were provided ad libitum 
access to a corn and soybean meal based commercial diet free of antibiotics and anti-
infectives that met or exceeded their nutrient requirements (NRC, 2012). Pigs were provided 
ad libitum access to water without antimicrobials via two nipple drinkers. 
 
Experimental Design  
In the challenge group, PK assessments were performed on the same animals pre and 
post disease challenge to evaluate the effect of PRRSV and Streptococcus suis coinfection on 
the PK profile of ceftiofur hydrochloride while controlling for biological variations in drug 
metabolism. To control for potential differences in the pharmacokinetic profile resulting from 
second exposure to the same drug, as well as differences in age due to the elapsed time 
between PK assessments, a control group was utilized. The control group was subjected to 
the same PK assessments at the same time points without being infected (Fig. 1). An initial 
PK assessment was conducted in both the challenge and control groups before viral and 
bacterial inoculation of the challenge group. Pigs were weighed 12 h before initiating the first 
PK assessment and these weights were used to calculate appropriate drug dosages. Feed and 
water were not restricted prior to weighing. The dose was rounded to the nearest whole 
milliliter. Pigs in both groups received a single IM injection, in the dorsolateral cervical neck, 
of ceftiofur hydrochloride at a dosage of 5 mg/kg BW. Blood samples were collected via the 
left or right jugular vein into 7 mL tubes containing lithium heparin (BD Vacutainer, 
Franklin Lakes, NJ) at 0, 10, 20, 40, 60 min and at 2, 4, 8, 16, 24, 36, and 48 h post injection 
to characterize the plasma ceftiofur concentration over time curves. During blood collection 
animals were manually restrained in dorsal recumbency in a “V” shaped trough constructed 
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of stainless steel. At the conclusion of the initial PK assessment, a 10 d washout period 
occurred for both groups. At the end of the washout period, the challenge group was 
inoculated with 2 mL of PRRSV isolate VR-2385 (105.75 50% tissue culture infective dose 
per mL) intranasally (IN) (Halbur et al., 1995). Eight days after PRRSV inoculation, the 
same pigs were inoculated with 2 mL of Streptococcus suis serotype 2 (1.23 x 109 cfu/mL) 
IN. One hour prior to receiving Streptococcus suis inoculation pigs were administered 5 mL 
of 1% acetic acid, divided between nostrils, to serve as a nasal irritant and predispose animals 
to infection (Pallares et al., 2003). Animals were observed daily and when clinical disease 
was evident in greater than 50% of the challenge group, a second PK assessment was 
completed in both the challenge and control groups. Pigs were re-weighed to calculate 
appropriate drug doses before the second PK assessment which followed the above outlined 
procedures. Clinical classification criteria suggesting disease were established a priori. To be 
considered “diseased” a pig had to exhibit one primary clinical criteria (rectal temperature 
greater than 39.4 °C or neurologic signs characterized by ataxia, paddling, and recumbency) 
together with one of the secondary clinical criteria (coughing, dyspnea, and nasal discharge).  
 
Inocula preparation 
PRRSV isolate VR-2385 was initially recovered from a sow herd in southwestern 
Iowa that experienced severe respiratory diseases in 3-16 wk old pigs and late-term abortions 
in 1991 (Halbur et al., 1995). This isolate has been used for experimental infection or 
challenge in numerous studies (Doeschl-Wilson et al., 2009; Opriessnig et al., 2007; 
Thanawongnuwech et al., 1998). VR-2385 strain was propagated in MARC-145 cells, a 
clone of the African monkey kidney cell line MA-104 (Kim et al., 1993). The cells were 
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cultured and maintained in RPMI-1640 Medium (Life Technologies, Grand Island, NY ) 
supplemented with 10% fetal bovine serum, 2 mM L-Glutamine, 0.05 mg/ml Gentamicin, 10 
unit/ml penicillin, 10 µg/ml Streptomycin, and 0.25 µg/ml Amphotericin. Virus titration was 
performed in 96-well plates of MARC-145 cells by inoculating 10-fold serial dilutions of the 
virus (100 µl per well), triplicate per dilution. After five day inoculation, virus-specific 
cytopathic effect was recorded and the plates were subjected to immunofluorescence staining 
with PRRSV-specific monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC) 
for confirmation of virus. The virus titers were determined according to the Reed and 
Muench method (Reed and Muench, 1938) and expressed as 50% tissue culture infective 
dose per milliliter (TCID50/ml).            
Streptococcus suis serotype 2, isolate ISU VDL #40634/94 was prepared according to 
the method described by Halbur et al., 2000. A challenge dose of 1.23 x 109 CFU/mL was 
used. The inoculum was checked for purity by streaking onto a BAP and incubating at 37°C 
in 5% CO2 air.  The Streptococcus suis serotype 2 challenge inoculum was tested for 
antimicrobial susceptibility to ceftiofur using in vitro semi-automated broth dilution 
technique known as modified minimum inhibitory concentration (MIC) in accordance with 
the Clinical and Laboratory Standards Institute performance standards (CLSI, 2013). The 
isolate was susceptible to ceftiofur at < 0.25 µg/ml. 
 
Diagnostic Sampling 
After PRRSV inoculation in the challenge group and before the second PK 
assessment, oral fluid samples were collected from both control and challenge groups to 
assess PRRSV status using a real-time PRRSV RT-PCR (Life Technologies, Grand Island, 
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NY) performed at Iowa State University Veterinary Diagnostic Laboratory (ISU VDL). The 
limited antemortem diagnostics available for detecting Streptococcus suis infection left 
clinical symptoms as the criteria used in determining infection status. Two days after 
completion of the second PK assessment, serum was tested for PRRSV nucleic acid using a 
real-time RT-PCR and for anti-PRRSV antibody using PRRS X3 ELISA (IDEXX, 
Westbrook, Maine) on all study animals to again confirm PRRSV infection in the challenge 
group and absence of PRRSV infection in the control group. 
 
Sample Management 
Blood samples were maintained on ice packs after collection until processing which 
occurred within 2 h of collection. Blood samples for ceftiofur analysis were centrifuged at 
1,000 x g for 10 min at 4°C to collect the plasma. Immediately after centrifugation the 
plasma was harvested, placed in cryovials, and frozen at -70 ° C until analysis. All samples 
were analyzed within 190 d after sample collection. Blood samples for confirming infection 
status were centrifuged using the above specifications to collect the serum. The serum was 
immediately placed into 5 mL Falcon round-bottom tubes (BD Biosciences, San Jose, CA) 
and taken to the ISU VDL for testing. 
  
Plasma Ceftiofur Analysis   
Samples were labeled in a coded manner, such that disease status and time point of 
samples were unknown to all individuals performing laboratory analysis. Plasma 
concentrations of ceftiofur were determined using liquid chromatography coupled with mass 
spectrometry (LC-MS). The LC-MS system consisted of an Agilent 1100 pump, autosampler, 
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and column compartment  (Agilent Technologies, Santa Clara, CA, USA) coupled to an ion 
trap mass spectrometer (LTQ , Thermo Scientific, San Jose, CA, USA). Ceftiofur 
concentrations (total ceftiofur, ceftiofur equivalents) were determined by cleavage of 
ceftiofur, its metabolites, and protein bound residues to desfuroylceftiofur with 
dithioerythritol (DTE) followed by derivatization with iodoacetamide. The stable derivative, 
desfuroylceftiofuracetamide (DCA), was then analyzed by LC-MS. Deuterated ceftiofur, d3-
ceftiofur was used as the internal standard which became d3-desfuroylceftiofuracetamide 
upon cleavage and derivatization. Cleanup of the derivatized samples was performed by solid 
phase extraction (SPE) using Oasis HLB cartridges (Waters Associates, Milford, MA, USA). 
Plasma samples, plasma calibrators, and QC samples, 200 µL, were treated with 3 mL of 
0.5% DTE in borate buffer, 0.05 N, pH 9.0 after addition of 10 µL of a 10 ng/µL solution of 
the internal standard, d3-ceftiofur. The samples were vortexed for 5 s and placed in a 50oC 
water bath for 15 minutes. Upon removal from the water bath and cooling to room 
temperature, 0.5 mL of 14% iodoacetamide in phosphate buffer (0.025 M, pH 7) was added 
followed by the samples being left in the dark for 30 minutes. After derivatization, the 
samples were cleaned up on an Oasis HLB SPE column (60 mg/3 mL) that was 
preconditioned with 1 mL of methanol followed by 1 mL of water. The sample was then 
transferred to the SPE column and allowed to pass slowly through the HLB column. The 
column was washed with a 1 mL portion of 5% (v/v) solution of methanol in water. The 
column was then dried for 5 min with a flow of nitrogen.  Elution of the derivatized samples 
was then performed with two 0.75 mL portions of 5% (v/v) acetic acid in acetonitrile. The 
eluate was dried at 50 oC with a stream of nitrogen in a Turbovap evaporator. The dry residue 
was reconstituted with 100 µL of 25% (v/v) acetonitrile in water and vortexed followed by 50 
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µL of water and vortexed. The tube contents were transferred to an autosampler vial fitted 
with a glass insert. The injection volume was set to 15 µL. The mobile phases consisted of A: 
0.1% formic acid in water and B: 0.1% formic acid in acetonitrile at a flow rate of 0.25 
mL/min. The mobile phase began at 10% B with a linear gradient to 95% B at 8 min, which 
was maintained for 1.5 min, followed by re-equilibration to 10% B. Separation was achieved 
with a ACE C18 column (ACE 3 C18, 150 mm x 2.1 mm, 3 µm particles, Mac-Mod 
Analytical, Chadds Ford, PA, USA) maintained at 40 °C. Desfuroylceftiofuracetamide 
(DCA) eluted at 3.70 min and the internal standard, d3-desfuroylceftiofuracetamide at 3.66 
min. Sequences consisting of plasma blanks, calibration spikes, QC samples, and porcine 
plasma samples were batch processed with a processing method developed in the Xcalibur 
software (Thermo Scientific, San Jose, CA, USA). The processing method automatically 
identified and integrated each peak in each sample and calculated the calibration curve based 
on a weighted (1/X) linear fit. Plasma concentrations of ceftiofur in unknown samples were 
calculated by the Xcalibur software based on the calibration curve. Results were then viewed 
in the Quan Browser portion of the Xcalibur software. The standard curve in porcine plasma 
was linear from 1 to 10,000 ng/mL.   
 
Pharmacokinetic Analysis 
Pharmacokinetic analyses of the plasma concentration data were performed with 
computer software (WinNonlin 5.2, Pharsight Corporation, Mountain View, CA, USA) using 
noncompartmental methods. The variables calculated included the area under the curve up to 
the last measured concentration (AUClast), area under the curve from time 0 to infinity 
(AUCINF) using the linear trapezoidal rule, percent of the AUC extrapolated to infinity (AUC 
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EXTRAP), plasma clearance per fraction of dose absorbed (Cl/F), apparent volume of 
distribution per fraction of dose absorbed (Vz/F), terminal half-life (T½), elimination rate 
constant (Kel), and mean residence time extrapolated to infinity (MRT). The maximum 
plasma concentration (CMAX) and time to maximum plasma concentration (TMAX) were 
determined directly from the plasma concentration data. The AUCEXTRAP was determined by 
multiplying the last measured plasma concentration by the elimination rate constant. The 
number of points to include in the estimation of the elimination rate constant was determined 
by visual inspection of the plasma profile and determined by linear regression of time and 
natural log (ln) of the plasma concentration. 
 
Statistical Analysis 
A mixed effect ANOVA model (SAS V.9.2, SAS Inst. Inc., Cary, NC) was used to 
compare PK parameters within the control and challenge groups between the first and second 
PK assessments as well as across groups. The statistical model included the PK parameter of 
interest as the response variable and the fixed effects of period (first or second PK 
assessment), disease (control or challenge group), and a disease*period interaction. Pig ID 
was included as a random effect and was nested within disease. A Tukey’s Honestly 
Significant Differences (HSD) Test was performed for testing difference among the four 
interacted disease*period levels. The Tukey adjusted CI and P values were reported. The PK 
parameter TMAX was logarithmically transformed before data analysis. Statistical significance 
was set a priori at values of P ≤ 0.05.  
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Results 
During the study, control animals remained clinically healthy and negative for 
PRRSV as examined by PRRSV PCR and ELISA.  In the challenge group, PRRSV virus was 
detected throughout the 12 d from infection to completion of the second PK assessment as 
determined by PRRSV PCR on serum and oral fluids. Challenge animals tested PRRSV 
ELISA positive at conclusion of the second PK assessment, 12 d post PRRSV inoculation. 
No adverse effects were observed following IM administration of ceftiofur 
hydrochloride at the labeled dosage of 5 mg/kg. Ceftiofur levels were below the limit of 
detection on baseline samples collected before ceftiofur administration in the first PK 
assessment, verifying animals had no recent ceftiofur administration, as well as before the 
second PK assessment, suggesting the 10 d washout period provided adequate time between 
studies to prevent any residual drug accumulation. 
No PK parameters within the control group were significantly different between the 
first and second PK assessments. In the challenge group, the AUCLAST, AUCINF, and CMAX 
were significantly lower in the second compared to the first PK assessment (Table 1). 
Volume of distribution per fraction of the dose absorbed (Vz/F) and Cl/F were significantly 
higher in the second compared to the first PK assessment. Comparing the control and 
challenge groups in the second PK assessment, the same PK parameters, with the exception 
of CMAX, were also significantly different between the groups. Figure 2 illustrates the plasma 
concentration-time curves for the challenge group between the first and second PK 
assessments. 
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Discussion  
The PK parameters measured within the control group were not significantly different 
between the first and second PK assessments. This suggested that previous drug exposure did 
not change subsequent drug metabolism in the challenge group. This also suggested that the 
washout period and change in age between the first and second PK assessments did not 
change subsequent drug metabolism. Consequently, a comparison of the PK assessments in 
the challenge group pre and post inoculation could be completed, and differences in PK 
parameters attributed to the change in disease status.  
The pharmacokinetics of ceftiofur hydrochloride in pigs coinfected with PRRSV and 
Streptococcus suis were significantly different compared to clinically healthy pigs. Challenge 
group animals received the same IM dose of ceftiofur hydrochloride relative to BW during 
both PK assessments, but demonstrated reduced plasma ceftiofur concentrations in the 
second PK after disease challenge. Coinfected pigs demonstrated a 17.6% decrease in AUC 
and a 22.7% reduction in CMAX, but showed a 23.2% increase in Cl/F and a 30.4% greater 
Vz/F.  
The pharmacokinetic parameters Cl/F and Vz/F were increased as a consequence of 
disease. Possible explanations for these changes include a decrease in bioavailability in 
coinfected animals or true increases in plasma clearance (CL) and volume of distribution 
(Vd). The CL and Vd cannot be determined directly from this study as it requires information 
on bioavailability assessed with IV pharmacokinetic data. The significant reductions in CMAX 
and AUC suggest bioavailability is decreased leading to reduced absorption of the drug into 
systemic circulation. Various physiologic factors can reduce drug bioavailability. Diseased 
animals may experience diminished circulation to the IM injection site decreasing tissue 
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perfusion and the proportion of drug which reaches systemic circulation. Coinfection may 
also result in changes to the pH of tissues affecting drug absorption. After IM administration 
the drug must cross several cell membranes before reaching systemic circulation, and this 
process is partly influenced by pH. Ceftiofur hydrochloride is a weak acid and crosses 
membranes more easily in a lower pH environment. Changes which lead to a higher pH may 
reduce ceftiofur absorption.  
Lower plasma concentrations and higher clearance rates reduce the likelihood of 
achieving effective plasma levels relative to Streptococcus suis MICs in the presence of 
PRRS virus. This has implications on treatment regimens when using ceftiofur products. 
Products that are labeled with a range of doses should be administered at the higher dose 
during PRRSV viremia, products that allow repeat dosing may be preferred, and treatment 
protocols that facilitate follow up treatment of pigs are critical to maximizing judicious use 
and return on antimicrobial investment. 
The FDA has prohibited certain extralabel drug uses (ELDU) of ceftiofur products.  
Ceftiofur can be used to treat or control an extralabel disease indication, but must be used in 
the species for which it’s approved and according to the labeled dosage regimen (dose, route, 
frequency, and duration of administration) (Federal Register, 2012).  There are three 
commonly used ceftiofur products approved for use in swine. Excenel and Naxcel (ceftiofur 
sodium sterile powder, Zoetis, Kalamazoo, MI) are both labeled at a dose of 3-5 mg/kg BW 
administered IM and repeated at 24 h intervals for a total of three consecutive days. Excede 
(ceftiofur crystalline free acid sterile suspension, Zoetis, Kalamazoo, MI) is labeled for a 
single IM injection at 5 mg/kg BW dose. Veterinarians cannot legally make dose adjustments 
past these label indications. This restricts the veterinarian’s ability to modify treatment 
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regimens when using ceftiofur products, and further supports the need for PK studies 
completed in both diseased and healthy animals to be included in the drug approval process. 
The ability of comparisons in the same animals to reduce biological variation and 
increase statistical power was demonstrated when evaluating CMAX which was not 
statistically significant when comparing across control and challenge groups in the second 
PK assessment, yet was significant when comparing the same pigs before and after 
challenge. This illustrates how comparisons completed on the same animal are more ideal as 
they control for individual variation in drug metabolism. 
A limitation of this study was variation in the severity of clinical symptoms 
associated with Streptococcus suis infection in the challenge group. Challenge animals were 
confirmed to have an acute PRRSV infection and had clinical symptoms consistent with 
Streptococcus suis infection including high fever, nasal discharge, coughing, sneezing, and/or 
dyspnea. Challenge animals did not however exhibit CNS signs such as ataxia, recumbency, 
or paddling. The second PK assessment could have been delayed to allow for the 
development of more severe clinical symptoms, however, with the previously published 
virulence of this co-infection model and the PK study requiring 12 blood draws in 48 h with 
associated handling stress, the PK assessment was initiated with milder clinical symptoms to 
prevent mortality of challenge group animals (Pallares et al., 2003). There were significant 
differences in PK parameters in the challenge group between the two PK assessments with 
these mild clinical signs, however, these effects may have been more pronounced if the 
clinical symptoms were allowed to progress.  
Results from this study were consistent with a previously reported study in which 
pigs infected with PRRSV experienced decreased plasma ceftiofur concentrations 
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(Tantituvanont et el. 2009). In this study PRRSV infected pigs demonstrated higher values of 
Vz/F and CL/F and lower values of AUC and CMAX consistent with the present study results, 
but also demonstrated lower values of MRT and T½ which were not documented in the 
current study. A commonality between these studies is a reduction in plasma ceftiofur 
concentrations. Additional studies examining the distribution of ceftiofur in extravascular 
tissues is needed to clarify the cause of the reduction in plasma concentrations. 
The results of the present study suggest coinfection with PRRSV and Streptococcus 
suis was associated with significant changes in the PK profile of ceftiofur hydrochloride. 
Coinfected animals experienced a reduced AUC and CMAX, but higher values of CL/F and 
Vz/F. These findings demonstrate the importance of understanding PRRSV status as viremia 
may impede treatment outcomes. Emphasis should be placed on disease prevention and 
diagnostic testing to confirm existing coinfections as opposed to treating empirically. 
Additional studies evaluating the effects of common coinfections in swine on different 
antimicrobial classes are needed to characterize PK changes which may impact treatment 
efficacy. Pharmacokinetic studies completed in both healthy and diseased pigs should be 
included in the drug approval process, particularly in antimicrobials where ELDU is 
prohibited. 
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CHAPTER 3 
 SUMMARY AND CONCLUSIONS 
 
Few studies have evaluated the impact of disease on pharmacokinetics of swine 
antimicrobials, however, the results of these studies consistently illustrate pharmacokinetics 
are altered as a consequence of disease. They also demonstrate a need for further research 
evaluating pharmacokinetics in various infection models and antimicrobial classes. The 
present research was conducted to provide additional information on how disease impacts the 
PK profile of ceftiofur, a commonly used antimicrobial in swine. A PRRSV and 
Streptococcus suis coinfection model was selected due to the common occurrence of this 
coinfection in the field, its significant impacts on production, and lack of effective 
Streptococcus suis control measures. 
Consistent with previous research, the results of the current study revealed the PK 
profile of ceftiofur was altered by disease. Coinfected pigs demonstrated a decrease in AUC 
and a reduction in CMAX, but showed an increase in Cl/F and a higher Vz/F. Similar to other 
studies, the exact cause for these alterations cannot be directly determined from trial results.  
Possible explanations for the changes seen in Cl/F and Vz/F include a decrease in 
bioavailability in coinfected animals or true increases in plasma clearance (CL) and volume 
of distribution (Vd). The CL and Vd cannot be calculated in this study as IV pharmacokinetic 
data was not available. This limits the ability to identify the cause of these alterations, but in 
knowing the challenge model, inferences can be made about how these changes developed. 
Ceftiofur is a highly protein bound drug. High levels of protein binding reduce the amount of 
drug diffusion from the plasma to the extravascular space, as only unbound drug can diffuse 
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into extracellular fluid (Papich, 2009). Protein binding also decreases the rate of ceftiofur 
elimination as ceftiofur elimination is primarily renal and only the free form of the drug is 
filtered (Papich, 2009; Beconi-Barker et al., 1997). Changes in drug interaction with protein 
may explain alterations in plasma clearance and volume of distribution. A decrease in protein 
interaction would create an increased fraction of the free form of ceftiofur, allowing more 
drug to deposit in tissues and be presented for renal elimination, thereby increasing both 
clearance and volume of distribution. Coinfection with PRRSV and Streptococcus suis 
results in a systemic inflammatory process. Inflammation may lead to a change in the total 
amount of protein present through alterations in protein type, development of fibrinous 
adhesions, or deposition of protein in body cavities. Inflammation also increases vascular 
perfusion and permeability allowing protein and protein bound drug to leave the vascular 
space and penetrate normally excluded tissues. 
Another possible explanation for the alterations in Cl/F and Vz/F, as previously 
discussed, is a decrease in bioavailability leading to reduced absorption of the drug into 
systemic circulation. Various physiologic factors can reduce drug bioavailability. Decreased 
bioavailability may result from diminished circulation to the injection site, reducing the 
amount of drug which enters systemic circulation, or alterations in pH which reduce 
ceftiofur’s ability to cross cellular membranes. 
To determine if the alterations in Cl/F and Vz/F were the result of changes in plasma 
clearance, volume of distribution, bioavailability, or a combination of these, information on 
ceftiofur bioavailability following IM administration is needed. Determining bioavailability 
requires IV pharmacokinetic data to compare the AUC between IV and IM routes of 
administration. Due to the lack of a commercially available IV formulation of ceftiofur 
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hydrochloride, the present study did not include IV pharmacokinetic data. The current study 
design would need modified to include this information through addition of an animal group. 
Similar to the challenge group, these animals would undergo two PK assessments, pre and 
post disease challenge, with IV as opposed to IM drug administration. This information 
would allow for calculation of the bioavailability following IM administration and for 
comparison of changes in bioavailability between healthy and diseased animals. 
The alterations in pharmacokinetic parameters in the current study suggest clinical 
efficacy of ceftiofur hydrochloride is altered in PRRSV and Streptococcus suis coinfected 
pigs, however, treatment efficacy was not directly evaluated. To accurately characterize the 
ceftiofur plasma concentration-time curve, the present pharmacokinetic assessment required 
12 blood draws in a 48 hour period with associated handling stress. This collection schedule 
presents added challenge to already diseased animals, confounding the relationship between 
ceftiofur administration in coinfected pigs and antimicrobial efficacy. Additionally, efficacy 
should be evaluated using a complete dosage regimen. Excenel is labeled for three 
consecutive days of treatment. The present pharmacokinetic assessment was conducted after 
a single IM injection as opposed to three injections administered 24 hours apart. Given these 
two factors, impact of disease on pharmacokinetics and antimicrobial efficacy are better 
evaluated separately. A more appropriate approach to evaluate efficacy involves conducting 
an initial PK trial, as in the present study, to determine the specific pharmacokinetic 
parameters altered as a consequence of disease. Based on these PK changes, 
recommendations for treatment regimen modifications can be made as warranted. A follow-
up study then conducted, using the same challenge model, to compare the efficacy of the 
modified treatment regimen to the labeled dosing recommendations. This approach provides 
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the most clinically relevant comparison and determines if treatment modifications developed 
from PK studies in diseased animals result in improved treatment efficacy. 
The results of the present study demonstrate the ability of comparisons completed in 
the same animals pre and post disease challenge to provide for a more ideal evaluation of the 
effect of disease on pharmacokinetics by controlling for individual variation in drug 
metabolism.  The majority of studies completed examining the impact of disease on 
pharmacokinetics have not utilized same animal comparisons. This difference in study design 
may reduce the ability to detect changes in PK parameters due to biological variation. The 
current research suggests study designs involving same animal comparisons are preferred, 
and should be utilized in combination with a control group to account for potential 
confounding variables. 
In evaluating previous literature, in combination with the present research, the same 
pharmacokinetic parameters are not uniformly affected between studies. The variation in 
pharmacokinetic parameters altered and the magnitude of effect indicate the relationship is 
likely antimicrobial and disease specific. This demonstrates the need for additional studies 
evaluating the impact of various infection models in different antimicrobial classes. 
Information from these studies will illustrate how various disease processes affect 
antimicrobials for use in swine, and allow for science based modifications to treatment 
regimens. In addition to examining the specific alterations occurring in the PK profile, focus 
on determining the cause of these changes is needed to better understand the impact of 
disease. This will require information on drug bioavailability and tissue concentrations in 
diseased animals. 
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It not only appears the relationship of disease on pharmacokinetics is reliant on the 
infection model and antimicrobial class, but on the severity of clinical symptoms. In the 
present study challenge animals met pre-established clinical criteria prior to initiation of the 
PK assessment. The clinical symptoms exhibited were, however, mild in nature compared to 
previously reported studies utilizing this challenge model in younger pigs. The mild clinical 
symptoms could be attributed to absence of full progression of disease prior to initiating the 
PK assessment, lack of environmental stressors, or age of trial animals. Study animals were 
older than the age range in which Streptococcus suis infections typically occur, due to the 
large volume of blood which must be collected in 48 hours. Significant alterations in the 
ceftiofur PK profile were still appreciated in diseased animals, but the magnitude of these 
changes may have been more pronounced had the disease process been more progressed.  In 
advanced systemic disease, physiologic processes in the body are more severely altered and 
may subsequently have a larger impact on drug kinetics.  
Extrapolation of the present study results to other antimicrobials and disease models 
is limited for several reasons. Other antimicrobials could possess different physical properties 
which affect how they respond to the disease state. The molecular weight, degree of protein 
binding, and hydrophilic vs. lipophilic nature of an antimicrobial influence how the drug 
distributes through the body.  A disease process which decreases protein binding, for 
example, would have a greater effect on a highly protein bound drug such as ceftiofur, as 
opposed to a drug with low protein binding. Additionally, metabolism and elimination may 
differ between antimicrobials. Ceftiofur primarily undergoes renal elimination, making it 
more susceptible to PK alterations when disease challenge leads to renal impairment. 
Another complication in generalizing study results to other antimicrobials is certain PK 
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parameters are used as predictors of clinical efficacy which differ among classes of 
antibiotics. Ceftiofur, being a time-dependent antimicrobial, is reliant on the time serum 
concentrations remain above the MIC (t > MIC) during the dosing interval. PK alterations 
which reduce the t >MIC would affect the clinical efficacy of ceftiofur, but would have less 
of an impact on concentration-dependent antimicrobials. 
Utilizing efficacious treatment protocols, which are appropriately targeted to a known 
disease indication, is essential to practicing judicious use of antimicrobials. Information 
gained on how disease impacts pharmacokinetics will allow for science based modifications 
to treatment regimens. Treatment modifications should maximize the pharmacokinetic 
principles which are the main predictors of clinical efficacy, while accounting for the altered 
PK profile in diseased animals.  These adjustments will more effectively treat disease while 
minimizing antimicrobial resistance.   
When using ceftiofur products, veterinarians are unable to make dose regimen 
adjustments beyond label indications due to prohibition of ELDU in major species of food-
producing animals. The basis for prohibiting ELDU was to preserve the effectiveness of 
cephalosporin drugs which are considered important in human medicine. The FDA was 
concerned certain ELDU may contribute to cephalosporin resistant strains of some 
pathogenic bacteria (Federal Register, 2012). This illustrates the importance of including PK 
studies conducted in diseased animals in the drug approval process.  Dosing regimens based 
on the profiles of healthy animals are not representative of where most drugs are applied in 
practice, and may reduce clinical efficacy of treatment.  Treatment regimens which are less 
efficacious are more likely to contribute to cephalosporin resistant strains of bacteria which 
the ELDU ban was originally established to prevent. 
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In summary, antimicrobial pharmacokinetics are affected by the diseased state. The 
present research illustrates how the PK profile of ceftiofur is altered by PRRSV and 
Streptococcus suis coinfection. Trial results demonstrate the importance of utilizing 
diagnostic testing to treat known disease indications as opposed to empirical treatment, and 
understanding PRRSV status as viremia may impede treatment outcomes. There remains a 
need for continuing research to evaluate the impact of disease on pharmacokinetics.  
Research should focus on evaluating different disease models and antimicrobial classes, 
determining the exact cause for these PK alterations, and assessing how severity of clinical 
symptoms affects the magnitude of PK changes.  Information gained needs to be included in 
the drug approval process to ensure the most efficacious dosing regimens are labeled for their 
respective disease indication. Knowledge on how the pharmacokinetic properties of 
antimicrobials are impacted by disease will allow for science based dosage regimens which 
maximize efficacy, minimize toxicity, and reduce the likelihood for developing antimicrobial 
resistance. 
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Figure 1. Timeline of trial events in a study examining the impact of PRRSV and Streptococcus suis co-infection on the 
pharmacokinetics of ceftiofur hydrochloride after intramuscular injection in pigs. PK=pharmacokinetic; PRRSV=porcine 
reproductive and respiratory syndrome virus, Strep suis =Streptococcus suis. 
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Figure 2. Challenge group plasma concentration curves comparison between first PK (pre 
disease challenge) and second PK (post disease challenge) in a study examining the impact 
of PRRSV and Streptococcus suis co-infection on the pharmacokinetics of ceftiofur 
hydrochloride after intramuscular injection in pigs. PK=pharmacokinetic.  
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Table 1. Summary of studies evaluating the impact of disease on pharmacokinetics of antimicrobials in swine. 
 
Impact of Disease on Pharmacokinetics in Swine 
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NSD = No Significant Difference,    = parameter increased,    = parameter decreased, ----- = parameter not evaluated 
† In combination with 25 mg SDM/kg BW 
‡ In combination with 25 mg SMX/kg BW 
*  Natural infection with the primary agent being PRRSV, however, at the conclusion of the study secondary bacterial 
agents were identified including Pasturella  multocida,   Bordetella bronchiseptica, and Streptococcus suis 
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Table 2. Ceftiofur hydrochloride non-compartmental pharmacokinetics after intramuscular 
administration (5 mg/kg) in challenge group pre and post inoculation in pigs. 
 
 
Challenge Group 1st PK1 vs. Challenge Group 2nd PK2 
Parameter3 Units 
Arithmetic Mean 
Difference 
2nd-1st PK 
Lower CI 
Difference 
Upper CI 
Difference 
  P-
value 1
st
 PK 2nd PK 
AUCEXTRAP % 5.01 5.82 0.81 -0.51 2.12 0.33 
AUCINF h*µg/ml 221.10 182.23 -38.88 -66.63 -11.12 0.0050 
AUCLAST h*µg/ml 209.91 171.75 -38.16 -63.16 -13.16 0.0024 
CL/F L/min/kg 0.38 0.47 0.09 0.03 0.15 0.0019 
CMAX µg/ml 20.61 15.93 -4.68 -8.15 -1.21 0.0069 
Log TMAX 
min 1.66 1.89 0.23 -0.03 0.50 0.10 
T ½ min 722.51 757.48 34.97 -46.86 116.81 0.62 
Kel L/min 0.00096 0.00092 -0.000042 -0.00015 0.000067 0.70 
MRT min 849.18 905.32 56.14 -36.72 149.00 0.34 
Vz/F L/kg 0.40 0.52 0.12 0.03 0.21 0.0054 
 
1 PK=pharmacokinetic 
2 WinNonlin 5.2, Pharsight Inc. Cary NC, USA 
3AUC extrapolated = percent of the AUC extrapolated; AUCINF = area under the curve 
extrapolated to infinity; AUCLAST= area under the curve up to the last measurable 
concentration; Cl/F = plasma clearance per fraction of the dose absorbed; CMAX = 
maximum plasma concentration; TMAX = time to CMAX; T ½ λz = terminal half-life; 
Kel=elimination rate constant; MRT= mean residence time extrapolated to infinity; 
Vz/F = volume of distribution per fraction of the dose absorbed.
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